NO323084B1 - Vaksine-sammensetninger - Google Patents

Vaksine-sammensetninger Download PDF

Info

Publication number: NO323084B1
Authority: NO; Norway
Prior art keywords: antigen; chitosan; accordance; mixture; vaccine
Prior art date: 1995-12-07

Application number

NO19982497A

Other languages

English (en)

Norwegian (no)

Other versions

NO982497D0 (no

NO982497L (no

Inventor

Lisbeth Illum

Original Assignee

West Pharmaceutical Service Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-07

Filing date

1998-06-02

Publication date

2006-12-27

1998-06-02 Application filed by West Pharmaceutical Service Dr filed Critical West Pharmaceutical Service Dr

1998-06-02 Publication of NO982497D0 publication Critical patent/NO982497D0/no

1998-06-02 Publication of NO982497L publication Critical patent/NO982497L/no

2006-12-27 Publication of NO323084B1 publication Critical patent/NO323084B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 74
229960005486 vaccine Drugs 0.000 title claims abstract description 42
108091007433 antigens Proteins 0.000 claims abstract description 99
102000036639 antigens Human genes 0.000 claims abstract description 99
239000000427 antigen Substances 0.000 claims abstract description 98
229920001661 Chitosan Polymers 0.000 claims abstract description 54
239000002671 adjuvant Substances 0.000 claims abstract description 12
230000028993 immune response Effects 0.000 claims description 11
206010022000 influenza Diseases 0.000 claims description 9
229920002101 Chitin Polymers 0.000 claims description 8
102000004169 proteins and genes Human genes 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
241000700605 Viruses Species 0.000 claims description 7
150000004676 glycans Chemical class 0.000 claims description 7
229920001282 polysaccharide Polymers 0.000 claims description 7
239000005017 polysaccharide Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
230000009885 systemic effect Effects 0.000 claims description 6
241000588832 Bordetella pertussis Species 0.000 claims description 4
102000003886 Glycoproteins Human genes 0.000 claims description 4
108090000288 Glycoproteins Proteins 0.000 claims description 4
206010043376 Tetanus Diseases 0.000 claims description 4
206010013023 diphtheria Diseases 0.000 claims description 4
230000002708 enhancing effect Effects 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
230000001681 protective effect Effects 0.000 claims description 4
239000000443 aerosol Substances 0.000 claims description 3
230000006196 deacetylation Effects 0.000 claims description 3
238000003381 deacetylation reaction Methods 0.000 claims description 3
230000036039 immunity Effects 0.000 claims description 3
239000004005 microsphere Substances 0.000 claims description 3
230000016379 mucosal immune response Effects 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
201000008827 tuberculosis Diseases 0.000 claims description 3
208000035473 Communicable disease Diseases 0.000 claims description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
244000052769 pathogen Species 0.000 claims description 2
108091033319 polynucleotide Proteins 0.000 claims description 2
102000040430 polynucleotide Human genes 0.000 claims description 2
239000002157 polynucleotide Substances 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
241000712461 unidentified influenza virus Species 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims 2
229940127557 pharmaceutical product Drugs 0.000 claims 2
108020004414 DNA Proteins 0.000 claims 1
102000053602 DNA Human genes 0.000 claims 1
230000006698 induction Effects 0.000 claims 1
230000001717 pathogenic effect Effects 0.000 claims 1
230000004044 response Effects 0.000 description 57
101710154643 Filamentous hemagglutinin Proteins 0.000 description 55
241000699670 Mus sp. Species 0.000 description 40
239000000243 solution Substances 0.000 description 32
210000001331 nose Anatomy 0.000 description 27
210000004072 lung Anatomy 0.000 description 19
210000002966 serum Anatomy 0.000 description 19
238000004458 analytical method Methods 0.000 description 18
230000003053 immunization Effects 0.000 description 18
238000002649 immunization Methods 0.000 description 17
239000000185 hemagglutinin Substances 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
101710154606 Hemagglutinin Proteins 0.000 description 11
101710093908 Outer capsid protein VP4 Proteins 0.000 description 11
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 11
101710176177 Protein A56 Proteins 0.000 description 11
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
230000003248 secreting effect Effects 0.000 description 9
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
229930195712 glutamate Natural products 0.000 description 8
238000000034 method Methods 0.000 description 8
238000003556 assay Methods 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
201000005702 Pertussis Diseases 0.000 description 5
239000000523 sample Substances 0.000 description 5
230000028327 secretion Effects 0.000 description 5
238000002255 vaccination Methods 0.000 description 5
108010055425 Bordetella pertussis filamentous hemagglutinin adhesin Proteins 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000004448 titration Methods 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
108010006232 Neuraminidase Proteins 0.000 description 3
102000005348 Neuraminidase Human genes 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
208000037798 influenza B Diseases 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000002435 venom Substances 0.000 description 3
231100000611 venom Toxicity 0.000 description 3
210000001048 venom Anatomy 0.000 description 3
ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
239000005630 Diquat Substances 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
241000607768 Shigella Species 0.000 description 2
208000004006 Tick-borne encephalitis Diseases 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000037797 influenza A Diseases 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007108 local immune response Effects 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
239000012475 sodium chloride buffer Substances 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 2
241000894007 species Species 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
206010073753 Fear of injection Diseases 0.000 description 1
229940124893 Fluvirin Drugs 0.000 description 1
108010084884 GDP-mannose transporter Proteins 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 description 1
206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000588747 Klebsiella pneumoniae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
101710198474 Spike protein Proteins 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
108010021711 pertactin Proteins 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19982497A 1995-12-07 1998-06-02 Vaksine-sammensetninger NO323084B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9525083.3A GB9525083D0 (en)	1995-12-07	1995-12-07	Vaccine compositions
PCT/GB1996/003019 WO1997020576A1 (en)	1995-12-07	1996-12-09	Vaccine compositions for intranasal administration comprising chitosan and use thereof

Publications (3)

Publication Number	Publication Date
NO982497D0 NO982497D0 (no)	1998-06-02
NO982497L NO982497L (no)	1998-06-02
NO323084B1 true NO323084B1 (no)	2006-12-27

Family

ID=10785093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19982497A NO323084B1 (no)	1995-12-07	1998-06-02	Vaksine-sammensetninger

Country Status (13)

Country	Link
US (2)	US6391318B1 (de)
EP (1)	EP0865297B1 (de)
JP (1)	JP4063876B2 (de)
AT (1)	ATE227134T1 (de)
CA (1)	CA2237529C (de)
DE (1)	DE69624726T2 (de)
DK (1)	DK0865297T3 (de)
ES (1)	ES2186809T3 (de)
GB (2)	GB9525083D0 (de)
NO (1)	NO323084B1 (de)
NZ (1)	NZ323973A (de)
PT (1)	PT865297E (de)
WO (1)	WO1997020576A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9419979D0 (en) *	1994-10-04	1994-11-16	Medeva Holdings Bv	Vaccine compositions
US5993852A (en) *	1997-08-29	1999-11-30	Pharmaderm Laboratories Ltd.	Biphasic lipid vesicle composition for transdermal administration of an immunogen
GB9725084D0 (en) *	1997-11-28	1998-01-28	Medeva Europ Ltd	Vaccine compositions
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
JP5124066B2 (ja) *	1999-03-24	2013-01-23	イギリス国	ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
GB9914412D0 (en) *	1999-06-22	1999-08-18	Worrall Eric E	Method for the preservation of viruses,bacteria and biomolecules
US20030206958A1 (en) *	2000-12-22	2003-11-06	Cattaneo Maurizio V.	Chitosan biopolymer for the topical delivery of active agents
EP1315672A4 (de)	2000-06-22	2006-04-26	Rxkinetix Inc	Verabreichungsträgerzusammensetzung und verfahren zur verabreichung von antigenen und anderen wirkstoffen
WO2002034287A2 (en) *	2000-10-27	2002-05-02	Pharmexa A/S	Therapeutic vaccine formulations containing chitosan
US7494669B2 (en) *	2001-02-28	2009-02-24	Carrington Laboratories, Inc.	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) *	2001-02-28	2004-08-17	Carrington Laboratories, Inc.	In-situ gel formation of pectin
ES2295391T3 (es)	2001-08-16	2008-04-16	Cmp Therapeutics Limited	Microparticulas de quitina y sus usos medicos.
WO2003028759A1 (en)	2001-09-28	2003-04-10	University Of South Florida	Rsv gene expression vaccine
BR0214280A (pt) *	2001-11-19	2005-01-11	Becton Dickinson Co	Composição farmacêuticas em forma particulada
DE60328481D1 (de) *	2002-05-14	2009-09-03	Novartis Vaccines & Diagnostic	Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) *	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
NZ536859A (en) *	2002-05-14	2007-11-30	Chiron Srl	Mucosal combination vaccines for bacterial meningitis
JP2005537244A (ja) *	2002-06-28	2005-12-08	ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド	療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
JP2006516609A (ja) *	2003-01-30	2006-07-06	カイロンソチエタアレスポンサビリタリミタータ	粘膜髄膜炎菌性ワクチン
CA2514667C (en) *	2003-01-30	2013-01-08	Chiron Corporation	Adjuvanted influenza vaccine
CA2516188C (en)	2003-02-14	2012-04-17	University Of South Florida	Chitosan-derivatives for gene delivery and expression
WO2004076664A2 (en) *	2003-02-21	2004-09-10	University Of South Florida	Vectors for regulating gene expression
US20040253211A1 (en) *	2003-04-30	2004-12-16	Nastech Pharmaceutical Company Inc.	Method for diagnosing and treating cancer
ZA200508480B (en) *	2003-05-01	2007-05-30	Archimedes Dev Ltd	Nasal administration of the LH-RH analog leuprolide
US8008255B2 (en)	2003-05-30	2011-08-30	Amylin Pharmaceuticals, Inc.	Methods and compositions for enhanced transmucosal delivery of peptides and proteins
GB0315632D0 (en)	2003-07-04	2003-08-13	West Pharm Serv Drug Res Ltd	Pharmaceutical formulations
US20070238676A1 (en) *	2003-12-04	2007-10-11	Mohapatra Shyam S	Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
US7968122B2 (en) *	2003-12-10	2011-06-28	Adventrx Pharmaceuticals, Inc.	Anti-viral pharmaceutical compositions
US20050129679A1 (en) *	2003-12-15	2005-06-16	Nastech Pharmaceutical Company Inc.	Method for opening tight junctions
US7740883B2 (en) *	2004-03-28	2010-06-22	University Of Debrecen	Nanoparticles from chitosan
JP2007536259A (ja) *	2004-05-06	2007-12-13	イヴレアファーマスーティカルズインコーポレイテッド	活性薬剤の送達のための粒子
US20090069226A1 (en) *	2004-05-28	2009-03-12	Amylin Pharmaceuticals, Inc.	Transmucosal delivery of peptides and proteins
US20050283004A1 (en)	2004-06-18	2005-12-22	Hopax Chemicals Manufacturing Co., Ltd.	Alkylsulfonated polyaminosaccharides
EP1790351A4 (de) *	2004-09-15	2009-11-04	Otsuka Pharma Co Ltd	Permukosale zusammensetzung und verfahren zur verbesserung der permukosalen absorption
WO2007086923A2 (en) *	2005-05-23	2007-08-02	University Of South Florida	Controlled and sustained gene transfer mediated by thiol-modified polymers
US20100272769A1 (en) *	2005-08-03	2010-10-28	Amcol International	Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) *	2005-08-03	2008-08-07	Amcol International	Virus-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) *	2005-08-03	2007-02-08	Amcol International Corporation	Virus-interacting layered phyllosilicates and methods of inactivating viruses
US8536324B2 (en) *	2005-10-21	2013-09-17	University Of South Florida	Method of drug delivery by carbon nanotube-chitosan nanocomplexes
WO2007059605A1 (en) *	2005-11-04	2007-05-31	Bio Syntech Canada Inc.	Composition and method for efficient delivery of nucleic acids to cells using chitosan
WO2007064755A2 (en)	2005-11-30	2007-06-07	Endo Pharmaceuticals Inc.	Treatment of xerostomia with a sulfur-containing antioxidant
AU2007285472B2 (en) *	2006-03-30	2013-10-24	Engene, Inc.	Non-viral compositions and methods for transfecting gut cells in vivo
WO2007148048A1 (en)	2006-06-20	2007-12-27	Cmp Therapeutics Limited	Compositions comprising chitin microparticles and their medical uses
EP2601969B1 (de) *	2006-09-29	2016-03-30	Takeda Vaccines, Inc.	Norovirus-impfstoff-formulierungen
EP2112923A1 (de)	2007-01-22	2009-11-04	Targacept Inc.	Intranasale, orale und sublinguale verabreichung von metanikotin-analogen
US20080182819A1 (en) *	2007-01-29	2008-07-31	Act Iii Licensing, Llc	Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
EP2431043A1 (de)	2007-05-23	2012-03-21	Amcol International Corporation	Mit Cholesterin interagierende Phyllosilikate zur Unterdrückung der gastrointestinalen Cholesterinabsorption
US20100266636A1 (en)	2007-09-18	2010-10-21	Ligocyte Pharmaceuticals, Inc.	Method of conferring a protective immune response to norovirus
CN104740624B (zh)	2007-09-18	2018-04-24	武田疫苗股份有限公司	赋予针对诺如病毒的保护性免疫应答的疫苗
CN101969976A (zh) *	2008-01-11	2011-02-09	美国政府健康与人类服务部秘书处	针对分枝杆菌的多肽疫苗和接种策略
WO2009108867A1 (en)	2008-02-27	2009-09-03	Amcol International Corporation	Methods of treating cardiovascular disorders associated with atherosclerosis
JP5852883B2 (ja) *	2008-08-08	2016-02-03	タケダワクチン，インコーポレイテッド	交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CN105567648B (zh) *	2009-04-15	2019-09-03	法国诗华大药厂	用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗
PH12014500093A1 (en)	2011-07-11	2014-03-17	Takeda Vaccines Inc	Parenteral norovirus vaccine formulations
US10279028B2 (en)	2012-04-24	2019-05-07	Ohio State Innovation Foundation	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
CN109876139A (zh)	2012-04-24	2019-06-14	俄亥俄州国家创新基金会	用于治疗和预防猪繁殖与呼吸综合征的组合物和方法
CN108715607B (zh) *	2018-04-12	2021-12-10	华南农业大学	重组霍乱毒素b亚基蛋白、pedv灭活疫苗及制备与应用
CN109172817B (zh) *	2018-08-16	2021-10-26	华中农业大学	猪流行性腹泻病毒减毒活疫苗壳聚糖微球的制备方法及其应用
EP3698773A1 (de)	2019-02-21	2020-08-26	Università degli Studi di Parma	Zusammensetzung und herstellung von pulvern mit nanoadjuvanzien zur mukosalen impfung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1261264A (en) *	1984-11-29	1989-09-26	Shigeo Suzuki	Immunopotentiating agents and method
US4950740A (en) *	1987-03-17	1990-08-21	Cetus Corporation	Recombinant diphtheria vaccines
US5554388A (en) *	1989-02-25	1996-09-10	Danbiosyst Uk Limited	Systemic drug delivery compositions comprising a polycationi substance
GB8904370D0 (en)	1989-02-25	1989-04-12	Cosmas Damian Ltd	Liquid delivery compositions
GB9202464D0 (en) *	1992-02-05	1992-03-18	Danbiosyst Uk	Composition for nasal administration
DK0789590T3 (da)	1994-09-23	2002-11-04	Zonagen Inc	Chitosaninduceret immunforstærkning
US5912000A (en) *	1994-09-23	1999-06-15	Zonagen, Inc.	Chitosan induced immunopotentiation
GB9419979D0 (en)	1994-10-04	1994-11-16	Medeva Holdings Bv	Vaccine compositions
KR19990028383A (ko) *	1995-06-26	1999-04-15	지 더블유 페이스	신규한 보조제 조성물 및 이것을 함유한 백신 제제
GB9522351D0 (en) *	1995-11-01	1996-01-03	Medeva Holdings Bv	Vaccine compositions

1995
- 1995-12-07 GB GBGB9525083.3A patent/GB9525083D0/en active Pending
1996
- 1996-12-09 PT PT96941743T patent/PT865297E/pt unknown
- 1996-12-09 WO PCT/GB1996/003019 patent/WO1997020576A1/en not_active Ceased
- 1996-12-09 DK DK96941743T patent/DK0865297T3/da active
- 1996-12-09 DE DE69624726T patent/DE69624726T2/de not_active Expired - Lifetime
- 1996-12-09 JP JP52109497A patent/JP4063876B2/ja not_active Expired - Fee Related
- 1996-12-09 CA CA002237529A patent/CA2237529C/en not_active Expired - Fee Related
- 1996-12-09 GB GB9811810A patent/GB2322801B/en not_active Expired - Fee Related
- 1996-12-09 NZ NZ323973A patent/NZ323973A/xx not_active IP Right Cessation
- 1996-12-09 AT AT96941743T patent/ATE227134T1/de active
- 1996-12-09 EP EP96941743A patent/EP0865297B1/de not_active Expired - Lifetime
- 1996-12-09 ES ES96941743T patent/ES2186809T3/es not_active Expired - Lifetime
1998
- 1998-06-01 US US09/088,185 patent/US6391318B1/en not_active Expired - Lifetime
- 1998-06-02 NO NO19982497A patent/NO323084B1/no not_active IP Right Cessation
2002
- 2002-05-08 US US10/141,312 patent/US7323183B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GB9525083D0 (en)	1996-02-07
PT865297E (pt)	2003-03-31
US7323183B2 (en)	2008-01-29
DE69624726T2 (de)	2003-09-18
US6391318B1 (en)	2002-05-21
CA2237529A1 (en)	1997-06-12
GB2322801A (en)	1998-09-09
DK0865297T3 (da)	2003-03-03
US20030039665A1 (en)	2003-02-27
NO982497D0 (no)	1998-06-02
EP0865297B1 (de)	2002-11-06
WO1997020576A1 (en)	1997-06-12
ES2186809T3 (es)	2003-05-16
AU705452B2 (en)	1999-05-20
NO982497L (no)	1998-06-02
NZ323973A (en)	2004-12-24
GB9811810D0 (en)	1998-07-29
EP0865297A1 (de)	1998-09-23
ATE227134T1 (de)	2002-11-15
JP4063876B2 (ja)	2008-03-19
AU1102597A (en)	1997-06-27
JP2000501412A (ja)	2000-02-08
DE69624726D1 (de)	2002-12-12
GB2322801B (en)	2000-01-19
CA2237529C (en)	2008-10-14

Legal Events

Date	Code	Title	Description
2016-08-15	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6391318B1 (en)	2002-05-21	Vaccine compositions including chitosan for intranasal administration and use thereof
EP0784485B1 (de)	2002-12-18	IMPFSTOFF-ZUSAMMENSETZUNGEN enthaltend teil-deacetyliertes Chitin
JP4137640B2 (ja)	2008-08-20	新規プロテオソーム−リポサッカリドワクチンアジュバント
JP3980884B2 (ja)	2007-09-26	プロテオソーム・インフルエンザ・ワクチン
MXPA97002336A (en)	1997-06-01	Vac compositions
NO323555B1 (no)	2007-06-11	Influensavaksine, farmasoytisk utstyr og anvendelse av kitosan.
EP2066332A1 (de)	2009-06-10	Grippeimpfstoff-mischung aus mannan und einem grippe-antigen
JP2002529427A (ja)	2002-09-10	薬学的作用物質の調合物および投与器具
JP2023091085A (ja)	2023-06-29	粘膜アジュバント
AU705452C (en)	2000-02-24	Vaccine compositions for intranasal administration comprising chitosan and use thereof
EP0721782B1 (de)	2000-08-16	Pertussistoxin enthaltender Influenzaimpfstoff
WO2008037033A1 (en)	2008-04-03	Flu vaccine admixture of mannan and flu antigen